The Lancet Infectious Diseases recently published results from a phase 2 clinical trial of the Lyme disease vaccine candidate, VLA15. The Valneva SE and Pfizer Inc.-funded study showed a strong immune response following a third booster... READ →
Destination
New York, NY

New York Health recommends several vaccines in 2025
Last reviewed
June 20, 2025